Risk factors for post-ERCP pancreatitis: a systematic review of clinical trials with a large sample size in the past 10 years

European Journal of Medical Research

Yue Li¹  Po Ding¹  Zong-Wu Suo¹  Mo Dong¹  Wen Li¹  Xing-Qiang Liu¹  Xi-Mo Wang¹  Jian-Jun Chen¹ 

[1] Department of Gastroenterology, People's Hospital of Tianjin, Jieyuan Road 190, Tianjin 300121, China

关键词: Systematic review;    Risk factors;    Pancreatitis;    Endoscopic retrograde cholangiopancreatography;   

Others  :  817403
DOI  :  10.1186/2047-783X-19-26

 received in 2013-07-08, accepted in 2014-04-11,  发布年份 2014

【 摘 要 】

Background

Post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common and most severe complication associated with diagnostic and therapeutic ERCP. A multivariate analysis of risk factors for PEP is essential for identifying patients at high risk and subsequently choosing other suitable diagnoses.

Methods

Pertinent publications were identified through systematic searches of MEDLINE, Elsevier, and Springer; we performed a systematic review of 12 clinical studies published in the past ten years, selected out of 451 reviewed articles, in which risk factors for pancreatitis were identified. Seven probable risk factors were evaluated, and outcomes expressed in the case of dichotomous variables, as an odds ratio (OR) (with a 95% confidence interval, 95% CI).

Results

When the risk factors were analyzed, the OR for female gender was 1.40 (95% CI 1.24 to 1.58); the OR for previous PEP was 3.23 (95% CI 2.48 to 4.22); the OR for previous pancreatitis was 2.00 (95% CI 1.72 to 2.33); the OR for endoscopic sphincterotomy was 1.42 (95% CI 1.14 to 1.78); the OR for precut sphincterotomy was 2.11 (95% CI 1.72 to 2.59); the OR for Sphincter of Oddi dysfunction was 4.37 (95% CI 3.75 to 5.09); and the OR for non-prophylactic pancreatic duct stent was 2.10 (95% CI 1.63 to 2.69).

Conclusions

It appears that female gender, previous PEP, previous pancreatitis, endoscopic sphincterotomy, precut sphincterotomy, Sphincter of Oddi dysfunction, and non-prophylactic pancreatic duct stent are the risk factors for post-ERCP pancreatitis.

【 授权许可】

   
2014 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Hori Y, Naitoh I, Nakazawa T, Hayashi K, Miyabe K, Shimizu S, Kondo H, Yoshida M, Yamashita H, Umemura S, Ban T, Okumura F, Sano H, Takada H, Joh T: Feasibility of endoscopic retrograde cholangiopancreatography‒related procedures in hemodialysis patients. J Gastroenterol Hepatol 2014, 29:648-652.
• [2]Colton JB, Curran CC: Quality indicators, including complications, of ERCP in a community setting: a prospective study. Gastrointest Endosc 2009, 70:457-467.
• [3]Cotton PB, Garrow DA, Gallagher J, Romagnuolo J: Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc 2009, 70:80-88.
• [4]Anderson MA, Fisher L, Jain R, Evans JA, Appalaneni V, Ben-Menachem T, Cash BD, Decker GA, Early DS, Fanelli RD: Complications of ERCP. Gastrointest Endosc 2012, 75:467-473.
• [5]Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, Overby CS, Aas J, Ryan ME, Bochna GS: Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001, 54:425-434.
• [6]Andriulli A, Loperfido S, Napolitano G, Niro G, Valvano MR, Spirito F, Pilotto A, Forlano R: Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007, 102:1781-1788.
• [7]Masci E, Mariani A, Curioni S, Testoni PA: Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy 2003, 35:830-834.
• [8]Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17:1-12.
• [9]Andriulli A, Clemente R, Solmi L, Terruzzi V, Suriani R, Sigillito A, Leandro G, Leo P, De Maio G, Perri F: Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002, 56:488-495.
• [10]Andriulli A, Solmi L, Loperfido S, Leo P, Festa V, Belmonte A, Spirito F, Silla M, Forte G, Terruzzi V: Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2004, 2:713-718.
• [11]Cheng CL, Sherman S, Watkins JL, Barnett J, Freeman M, Geenen J, Ryan M, Parker H, Frakes JT, Fogel EL: Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol 2006, 101:139-147.
• [12]Xia YZY, Yu JW, Zhang B: Risk factors for acute pancreatitis induced by ERCP. Chin J Dig Endosc 2004, 10:78-84.
• [13]Perney P, Berthier E, Pageaux GP, Hillaire-Buys D, Roques V, Fabbro-Peray P, Melki M, Hanslik B, Bauret P, Larrey D: Are drugs a risk factor of post-ERCP pancreatitis? Gastrointest Endosc 2003, 58:696-700.
• [14]Matsubayashi H, Fukutomi A, Kanemoto H, Maeda A, Matsunaga K, Uesaka K, Otake Y, Hasuike N, Yamaguchi Y, Ikehara H: Risk of pancreatitis after endoscopic retrograde cholangiopancreatography and endoscopic biliary drainage. HPB (Oxford) 2009, 11:222-228.
• [15]Testoni PA, Mariani A, Giussani A, Vailati C, Masci E, Macarri G, Ghezzo L, Familiari L, Giardullo N, Mutignani M: Risk factors for post-ERCP pancreatitis in high-and low-volume centers and among expert and non-expert operators: a prospective multicenter study. Am J Gastroenterol 2010, 105:1753-1761.
• [16]Tsuyuguchi T, Okugawa T, Yokosuka O: Risk factors for post‒endoscopic retrograde cholangiopancreatography pancreatitis: prospective single‒institution study. Dig Endosc 2007, 19:S49-S51.
• [17]Vandervoort J, Soetikno RM, Tham TC, Wong RC, Ferrari AP Jr, Montes H, Roston AD, Slivka A, Lichtenstein DR, Ruymann FW: Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002, 56:652-656.
• [18]Wilcox CM, Phadnis M, Varadarajulu S: Biliary stent placement is associated with post-ERCP pancreatitis. Gastrointest Endosc 2010, 72:546-550.
• [19]Zhou W, Li Y, Zhang Q, Li X, Meng W, Zhang L, Zhang H, Zhu K, Zhu X: Risk factors for postendoscopic retrograde cholangiopancreatography pancreatitis: a retrospective analysis of 7,168 cases. Pancreatology 2011, 11:399-405.
• [20]Akashi R, Kiyozumi T, Tanaka T, Sakurai K, Oda Y, Sagara K: Mechanism of pancreatitis caused by ERCP. Gastrointest Endosc 2002, 55:50-54.
• [21]Sai JK, Suyama M, Kubokawa Y, Watanabe S: Diagnosis of mild chronic pancreatitis (Cambridge classification): comparative study using secretin injection-magnetic resonance cholangiopancreatography and endoscopic retrograde pancreatography. World J Gastroenterol 2008, 14:1218-1221.
• [22]Bergman J, van Berkel AM, Bruno M, Fockens P, Rauws E, Tijssen J, Tytgat G, Huibregtse K: Is endoscopic balloon dilation for removal of bile duct stones associated with an increased risk for pancreatitis or a higher rate of hyperamylasemia? Endoscopy 2001, 33:416-420.
• [23]Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, Moore JP, Fennerty MB, Ryan ME, Shaw MJ: Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996, 335:909-919.
• [24]Simmons D, Petersen B, Gostout C, Levy M, Topazian M, Baron T: Risk of pancreatitis following endoscopically placed large-bore plastic biliary stents with and without biliary sphincterotomy for management of postoperative bile leaks. Surg Endosc 2008, 22:1459-1463.
• [25]Ueki T, Otani K, Fujimura N, Shimizu A, Otsuka Y, Kawamoto K, Matsui T: Comparison between emergency and elective endoscopic sphincterotomy in patients with acute cholangitis due to choledocholithiasis: is emergency endoscopic sphincterotomy safe? J Gastroenterol 2009, 44:1080-1088.
• [26]Sherman S, Ruffolo TA, Hawes RH, Lehman GA: Complications of endoscopic sphincterotomy: a prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology 1991, 101:1068-1075.
• [27]Fogel EL, Eversman D, Jamidar P, Sherman S, Lehman GA: Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy 2002, 34:280-285.
• [28]Freeman ML, Guda NM: ERCP cannulation: a review of reported techniques. Gastrointest Endosc 2005, 61:112-125.
• [29]Behar J, Corazziari E, Guelrud M, Hogan W, Sherman S, Toouli J: Functional gallbladder and sphincter of oddi disorders. Gastroenterology 2006, 130:1498-1509.
• [30]Choudhary A, Bechtold ML, Arif M, Szary NM, Puli SR, Othman MO, Pais WP, Antillon MR, Roy PK: Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc 2011, 73:275-282.
• [31]Tsujino T, Komatsu Y, Isayama H, Hirano K, Sasahira N, Yamamoto N, Toda N, Ito Y, Nakai Y, Tada M: Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005, 3:376-383.